AI Article Synopsis
- Sofpironium bromide (marketed as ECCLOCK in Japan) is a topical gel that helps reduce excessive sweating by blocking specific receptors in sweat glands.
- The gel gained its first approval in Japan in September 2020 for treating primary axillary hyperhidrosis (PAH).
- Ongoing clinical studies in the USA aim to evaluate the safety and effectiveness of a stronger 15% formulation of the gel for PAH treatment.
Article Abstract
Sofpironium bromide (ECCLOCK in Japan) gel is a topical anticholinergic agent developed by Bodor Laboratories and licenced to Brickell Biotech for the treatment of hyperhidrosis. The drug is designed to reduce sweating by inhibiting M3 muscarinic receptors in eccrine glands at the application site. In September 2020, sofpironium bromide gel 5% received its first approval in Japan for the treatment of primary axillary hyperhidrosis (PAH). Clinical studies are currently ongoing in the USA to assess the safety and efficacy of sofpironium bromide gel 15% in PAH. This article summarizes the milestones in the development of sofpironium bromide gel leading to this first approval for the treatment of PAH.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s40265-020-01438-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of sofpironium in treatment of primary hyperhidrosis: a systematic review.
J Dermatolog Treat
December 2025
Faculty of Medicine, University of Kalamoon, Al_Nabk, Syria.
Background: Primary axillary hyperhidrosis has limited noninvasive and effective treatment, and we present the use of sofpironium bromide as a promising treatment option. We aimed to assess the efficacy and safety of sofpironium in patients with primary hyperhidrosis.
Methods: We systematically searched the databases for Studies that assessed sofpironium bromide in patients with primary axillary hyperhidrosis.
Efficacy of 5% sofpironium bromide gel in Duchenne muscular dystrophy with palmoplantar hyperhidrosis: A retrospective case study.
J Dermatol
January 2024
Department of Nursing, National Hospital Organization Nagara Medical Center, Gifu, Japan.
Article Synopsis
- * A study examined the effectiveness of 5% sofpironium bromide gel in treating secondary hyperhidrosis in three patients aged 28 to 32 with advanced DMD and showed promising results.
- * After 5 weeks of treatment, patients demonstrated significant reductions in hyperhidrosis severity and sweat production, with an average decrease of 53.7% in palm sweat over 7 weeks and no major side effects, suggesting potential for further research in this area.
Efficacy of sofpironium bromide gel on clozapine-induced hypersalivation in patients with treatment-resistant schizophrenia: double-blind, controlled crossover study.
BJPsych Open
January 2023
Department of Psychiatry, Gifu University Graduate School of Medicine, Gifu, Japan.
Article Synopsis
- Hypersalivation linked to clozapine is a common issue for patients with treatment-resistant schizophrenia, prompting a search for effective treatments.
- A study tested sofpironium bromide gel against a placebo in a double-blind, controlled crossover format involving 16 patients, measuring saliva production and salivation severity over a series of weeks.
- Results showed a significant reduction in saliva volume, over 40% decrease in later weeks, and effects persisted even after stopping treatment, suggesting the gel is an effective option for managing this side effect.
Hyperhidrosis: A Review of Recent Advances in Treatment with Topical Anticholinergics.
Dermatol Ther (Heidelb)
December 2022
Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Article Synopsis
- * A search of PubMed and Embase revealed several anticholinergics under investigation for HH, including glycopyrrolate, oxybutynin, sofpironium bromide, and umeclidinium, with glycopyrrolate being the only FDA-approved option.
- * The findings suggest that understanding these topical treatments is crucial for managing HH, and although safety data is limited, the emerging treatments have minimal known risks for patients.
Hyperhidrosis: disease aetiology, classification and management in the light of modern treatment modalities.
Postepy Dermatol Alergol
April 2022
Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdansk, Gdansk, Poland.
Article Synopsis
- - Hyperhidrosis is a condition where the sweat glands produce excessive sweat, which doesn't meet the body's temperature control needs.
- - Current treatments for hyperhidrosis are inadequate, creating significant social and economic challenges for those affected.
- - Researchers are exploring new treatment options, including topical treatments, oral medications, minimally-invasive procedures, and surgery, aiming to improve patient outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!